Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- View the talks
-
1. Streptococcus pneumoniae: serotype diversity and epidemiology
- Dr. Bambos Charalambous
-
2. Tuberculosis: new treatments in evolution
- Prof. Stephen Gillespie
-
3. Current drugs for TB treatment
- Dr. Kasha Singh
-
4. Global progress in TB vaccine development
- Prof. Helen McShane
-
5. Management of MDR and XDR TB
- Prof. Martin Boeree
-
6. Non-tuberculous mycobacterial pulmonary disease (NTM-PD)
- Prof. Jakko van Ingen
-
7. The making of an influenza pandemic
- Prof. Jonathan Van-Tam
-
8. Responding to pandemic influenza
- Prof. Jonathan Van-Tam
- Dr. Chloe Sellwood
-
9. Controlling pandemic flu
- Prof. John Oxford
-
10. The future of influenza vaccines
- Dr. Marc P. Girard
-
11. Emerging or newly discovered viral causes of acute lower respiratory tract infections worldwide
- Dr. Marietjie Venter
- Mrs. Orienka Hellferscee
-
12. RSV vaccine development
- Prof. Ruth Karron
-
13. Respiratory mycoplasmas
- Prof. Stephen Gillespie
-
14. Infection in the cystic fibrosis lung
- Dr. Stuart Elborn
-
15. The role of infection at COPD exacerbations
- Prof. Wisia Wedzicha
-
16. An overview of non-cystic fibrosis bronchiectasis
- Dr. Maeve P. Smith
-
18. Pathogen discovery in the respiratory tract
- Dr. H. Rogier van Doorn
-
19. Aspergillosis infections and the lung
- Prof. Rosemary Barnes
-
20. Parasitic lung infections: protozoa, cestodes & trematodes
- Dr. Vannan Kandi Vijayan
-
21. Parasitic lung infections: nematodes
- Dr. Vannan Kandi Vijayan
-
22. Improving respiratory diagnostics (viruses)
- Prof. David Murdoch
Printable Handouts
Navigable Slide Index
- Introduction
- Characteristics of pandemic influenza (1)
- Characteristics of pandemic influenza (2)
- "It’s not a case of if, but when"
- Healthcare impact
- Societal impacts of a pandemic
- The emergency planning cycle
- Pandemic preparedness
- Aspects of planning and response
- Monitoring levels of illness (surveillance)
- "Total health surveillance"
- Monitoring the patient pathway
- Monitoring international spread
- Public health countermeasures
- Implementation of PH interventions
- Effectiveness of PH interventions
- Antiviral drugs in use
- Efficacy of antiviral drugs
- Framework for management of antiviral drugs
- Influenza vaccine manufacturing time-table
- Main problem of pandemic vaccines
- Aspects of pandemic vaccines
- Potential of pandemic vaccines
- Pre-pandemic vaccines?
- Healthcare continuity
- Communications
- Principles of pandemic communications
- Bioethical issues
- Training and exercising
- Summary
- Pandemic influenza book
- Further reading
Topics Covered
- Healthcare and societal impacts of a pandemic
- Pandemic preparedness
- Surveillance and monitoring of a pandemic
- Public health countermeasures
- Antiviral drugs (influenza)
- Pandemic influenza vaccines
- Healthcare capacity and capability
- Pandemic communications
- Bioethical issues
- Training and exercising
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Van-Tam, J. and Sellwood, C. (2014, December 2). Responding to pandemic influenza [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 31, 2024, from https://doi.org/10.69645/XNIJ1458.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Jonathan Van-Tam, Grant/Research Support (Principal Investigator): GlaxoSmithKline, F. Hoffmann La-Roche.
- Dr. Chloe Sellwood has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Infectious Diseases
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, and
welcome to this lecture entitled
"Responding To Pandemic Influenza."
My name is Jonathan Van-Tam.
I'm a Professor of Health Protection
at the University of Nottingham.
For this lecture, I shall
be joined by my colleague
from NHS England, Dr.
Chloe Sellwood, who
will introduce
herself in due course.
Hello.
My name is Dr. Chloe Sellwood,
and I'm the Pandemic Influenza
Resilience Manager for NHS England.
Now,
this is the second lecture
in a short pandemic series, and
it focuses, rather than on what
pandemics are, about how,
in terms of public health,
we respond to them.
So it's a good idea to have
listened to the first lecture
and studied the
material to go with it
or potentially to have done your
own reading about what influenza
pandemics are, how they're formed,
and their main characteristics.
You will really need
this kind of background
to get the most out of
this second lecture.
1:10
To begin with, let's remind
ourselves just a little bit
about the characteristics
of pandemic influenza.
Remember that these are
repetitive phenomena.
But in terms of when
they're going to occur,
we really just can't predict
at all when that will be,
and we can't predict
how severe they will be.
They could be no more severe
than a winter epidemic,
but they could, on
the other hand, be
incredibly severe, as
was the case in 1918.
But we can say that there are
recurrent features of influenza
A viruses, and as long as we
have influenza A in circulation,
the possibility of pandemics
will always be there.
In human history so far, we can only
say that the subtypes of influenza
A, H1, H2, and H3, are the
ones that have caused pandemics,
but we simply can't rule out the
very large variety of influenza
A viruses that exist in the
animal kingdom, particularly
in the natural reservoir,
wild water birds.
And if you think about
the recent history,
you would, like me, be concerned
about the potential pandemic threat
from H5N1, and also, and very
recently, the threat from H7N9
in China.
And it's these kind of concerns
that drive our continued vigilance
and the need to prepare
for pandemic influenza
and to be ready to respond
in an appropriate way.